Bispecific antibody molecule
View Patent ↗A first bispecific antibody molecule comprises at least one binding site with a variable domain on a light chain (V L ) and a variable domain for the T-cell receptor CD-28, linked thereto on a heavy chain (V h ). The antibody molecule further comprises at least one binding site with a variable domain on a heavy chain (V H ) and a variable domain for a tumour antigen, linked thereto on a light chain (V L ). The variable domains on the heavy chains for both specificities are connected to each other by means of a peptide linker. A second bispecific antibody molecule is bivalent for CD-28 and at least monovalent for the tumour antigen.
1. A recombinant bispecific antibody molecule with a first binding site for the CD28 molecule and a second binding site for a tumor-associated cell-surface antigen, wherein the variable domains of the respective heavy chain (V H ) of the two binding sites are joined together via a peptide linker that contains the amino acid sequence Ala-Ser-Thr-Lys-Gly-Pro-Ser-Val-Phe-Pro-Leu-Ala-Pro-Ser-Ser-Ser-Gly-Ser-Gly (SEQ ID NO: 2).
2. The antibody molecule as claimed in claim 1 , wherein the tumor-associated cell-surface antigen is selected from the group consisting of melanoma-associated proteoglycan, HER-2/neu and CD20.
3. The antibody molecule as claimed in claim 2 , wherein the tumor-associated cell-surface antigen is melanoma-associated proteoglycan.
4. The antibody molecule as claimed in one of the claims 1 to 3 , which has the sequence SEQ ID NO: 3.
5. A pharmaceutical composition containing an antibody molecule as claimed in one of the claims 1 to 3 and a pharmaceutically acceptable carrier.
6. A method for treating a patient having cancer comprising administering a sufficient amount of the bispecific antibody of any of claims 1 - 3 .